Clinical Trials Browser

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms, Castration-Resistant

Prostatic Neoplasms

Metastatic Castration-sensitive Prostate Cancer

Prostatic Neoplasms

Urinary Bladder Neoplasms

Urinary Bladder Neoplasms

Metastatic Castrate-sensitive Prostate Cancer

Non-Muscle Invasive Bladder Neoplasms

Non-Muscle Invasive Bladder Neoplasms

Metastatic Castration-Resistant Prostate Cancer

Non-Muscle Invasive Bladder Neoplasms

Prostatic Neoplasms

Metastatic Castration-resistant Prostate Neoplasms

Prostatic Neoplasms, Castration-Resistant

Urinary Bladder Neoplasms

Prostatic Neoplasms

Prostatic Neoplasms

Carcinoma, Carcinoma, Renal Cell

Prostatic Neoplasms

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Neoplasm Metastasis

Metastatic Castration-resistant Prostate Cancer

Locally Advanced or Metastatic Unresectable Urothelial Cancer

Clear-cell metastatic renal cell carcinoma, Kidney Neoplasms

Non-Muscle Invasive Bladder Neoplasms

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

Disease, Prostatic Neoplasms

Urothelial Cancer

Prostatic Neoplasms

Carcinoma, Renal Cell, von Hippel-Lindau Disease

Urinary Bladder Neoplasms

Carcinoma, Renal Cell

Urinary Bladder Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

Prostatic Neoplasms

Carcinoma, Renal Cell

Prostatic Neoplasms

Oligometastatic Prostate Cancer (OMPC)

Prostatic Neoplasms

Prostatic Neoplasms

Non-Muscle Invasive Bladder Neoplasms

Non-Muscle Invasive Bladder Neoplasms

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Renal Cell

Carcinoma, Carcinoma, Renal Cell, Neoplasm Metastasis

Intermediate Risk Non-Muscle Invasive Bladder Cancer

Non-muscle Invasive Bladder Cancer With Carcinoma in Situ

Biochemically Recurrent Prostate Cancer

Clinical Trials

SPARTAN

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

TITAN

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

MAGNITUDE

PROTEUS

AMPLITUDE

PRIMORDIUM

SunRISe-2

SunRISe-3

LIBERTAS

SunRISe-5

MoonRISe-1

A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer.

MoonRISe-3

MEVPRO-3

KLK2-comPAS

KLK2-PASenger

VOLGA

Solar-Stage

A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer

LITESPARK-033

MK-5684-004

FORAGER-2

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

TROPiCS-04

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

A Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC

Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study

Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.

EV-302

MK-2400-001

MK-6482-043

TroFuse-031

LITESPARK-034

NILE

KEYNOTE-866

VECTRA-01

Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)

PSMAddition

PSMA-DC

EvoPAR-PR01

The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)

PATAPSCO

TIM

Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)

SAMETA

ABLE-32

ABLE-22

ARASTEP